Features:
- Drug & excipient placed within the Tri-fold of the balloon to ensure minimum drug loss during transition.
- Used UREA as an excipient, which forms a crystalline structure with paclitaxel.
- Crystalline matrix allows stable & firm drug coating during storage and handling at the same time enables quick dissolution & rapid release of Paclitaxel at the vessel wall upon inflation.
- Paclitaxel is loaded at a dose of 3 micrograms/mm2 & ensures effective drug concentration (1.98ng/mg) in the vascular wall for more than 28 days to inhibit restenosis.
Product specification
| Diameter /mm | Length/mm | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 9 | 12 | 14 | 16 | 18 | 20 | 24 | 28 | 31 | 35 | 38 | |
| 2.0 | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ |
| 2.5 | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ |
| 2.75 | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ |
| 3.0 | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ |
| 3.5 | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ |
| 4.0 | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ |
| 4.5 | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ |